Effect of salicin on gut inflammation and on selected groups of gut microbiota in dextran sodium sulfate induced mouse model of colitis
- 17 November 2013
- journal article
- research article
- Published by Springer Nature in Inflammation Research
- Vol. 63 (2) , 161-169
Abstract
Objective and design This study was undertaken to evaluate the anti-inflammatory effect of the pure compound salicin on dextran sulfate sodium (DSS)-induced colitis in a mouse model and to quantify the major gut bacteria during the treatment. Material or subjects Experimental colitis was induced in Swiss albino mice by dissolving 2 % DSS in their drinking water for 7 days. Five mice were used in each group. Treatment Salicin (100 and 200 mg per body weight) was administered daily through oral gavage for 7 days. Methods Disease activity index (DAI), colon length, myeloperoxidase (MPO) assay, pro-inflammatory cytokine expression, histological changes and absolute number of gut microbiota were measured after treatment. Student’s t test was applied for statistical analysis. Results Salicin significantly attenuated DSS-induced DAI scores, shortening of colon length and tissue MPO activity. Salicin administration also effectively and dose-dependently prevented pro-inflammatory cytokine expression in DSS-induced colitis mice. Histological examination indicated that salicin suppressed edema, mucosal damage and the loss of crypts induced by DSS. Oral administration of salicin in DSS-treated mice prevented loss of gut microbiota during the short period of treatment. Conclusions Salicin has an anti-inflammatory effect, and it may have therapeutic value in ameliorating inflammation during colitis.Keywords
This publication has 37 references indexed in Scilit:
- Intravenous Injection of Endogenous Microbial Components Abrogates DSS-Induced ColitisDigestive Diseases and Sciences, 2011
- Real-Time Analysis of Mucosal Flora in Patients with Inflammatory Bowel Disease in IndiaJournal of Clinical Microbiology, 2010
- Myeloperoxidase: a target for new drug development?British Journal of Pharmacology, 2007
- Therapeutic Action of Ghrelin in a Mouse Model of ColitisGastroenterology, 2006
- Role of TNF‐αin muscularis inflammation and motility disorder in a TNBS‐induced colitis model: clues from TNF‐α‐deficient miceNeurogastroenterology & Motility, 2006
- Aetiology of inflammatory bowel disease (IBD): Role of intestinal microbiota and gut-associated lymphoid tissue immune responseClinical Nutrition, 2005
- Immunoregulation in the gut: success and failures in human diseaseGut, 2002
- The Immunology of Mucosal Models of InflammationAnnual Review of Immunology, 2002
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- More accurate diagnosis of irritable bowel syndrome by the use of 'non-colonic' symptomatology.Gut, 1991